Epidermal growth factor receptor (EGFR) mutation is a typical biomarker, commonly seen in non-small cell lung cancer (NSCLC). NSCLC patients with EGFR mutations have revealed significant prolonged survival rates. Detection of EGFR mutation has been accentuated, as it leads to increased survival rates for patients with lung cancer in targeted therapy.
An exclusive supplier of PNA, Panagene developed an EGFR mutation detection kit, named PNAClamp¢‚. PNAClamp™ is a real-time polymerase chain reaction (PCR)-based assay to identify the presence of EGFR mutations. The device detects a minute amount of 29 mutant DNA types amongst abundant wild-type DNAs. In addition, it enables users to prognose and assist in management of metastatic diseases, which results in the development of targeted therapy to improve the survival of patients.
Benefits of the product are as follows:
– Analysis through Real-time PCR: short turnaround time
– High sensitivity: It can even detect 1% of DNA mutation
– Convenient and quick interface for data analysis
– Simple experiment process with master mix type
– Identical protocol can save time
Through clinical demonstrations with global pharmaceutical companies, Panagene has manufactured mutation detection kits for EGFR, KRAS, PIK3CA, and more. Certified by FDA and CE, Panagene has exported to 27 organizations located in Asia, Europe, and the Middle East.
Korean-Products.com | Blog Magazine of Korean products, brands and Goods
